NVO - Eli Lilly Expands Fight Against Counterfeit Obesity Drug Zepbound With New Legal Actions | Benzinga
Eli Lilly & Co. (NYSE:LLY) has intensified its fight against counterfeit versions of its popular obesity drug, Zepbound, by initiating additional legal proceedings against companies selling compounded versions of the medication.
What Happened: The pharmaceutical company filed several new lawsuits on Thursday against various establishments, including medical spas and wellness centers, for promoting their products using Lilly’s brand names, Mounjaro and Zepbound, reported Bloomberg. The company accused these businesses of trademark violations, false advertising, and unfair competition.
Lilly has initiated 11 legal actions, alleging trademark violations, false advertising, and unfair competition. These lawsuits target companies selling counterfeit drugs under the names tirzepatide, which is the generic name for Mounjaro, and Zepbound.
The U.S. regulators permit pharmacies to produce copycat versions of drugs that are in short supply, a practice known as compounding. ...